Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Brazilian lawmaker denouncing vaccine deal wears bullet-proof vest to hearing

Published 06/25/2021, 05:55 PM
Updated 06/25/2021, 09:56 PM
© Reuters. Brazilian Federal Deputy Luis Miranda walks before a meeting of the Parliamentary Inquiry Committee (CPI) to investigate government actions and management during the coronavirus disease (COVID-19) pandemic, at the Federal Senate in Brasilia, Brazil June 2

By Maria Carolina Marcello

BRASILIA (Reuters) -A Brazilian congressman who has denounced alleged wrongdoing in a 1.6 billion reais ($323 million) COVID-19 vaccine contract signed by Brazil's government arrived at a Senate commission inquiry on Friday wearing a bullet-proof vest for safety.

Congressman Luis Miranda and his brother Luis Ricardo Miranda, the whistleblower at the Health Ministry who raised suspicions about the vaccine deal with India's Bharat Biotech, are the key witnesses in a hearing underway on Friday.

The parliamentary inquiry is looking into the government's handling of the coronavirus pandemic that has killed more than half a million people in Brazil, and accusations that it deliberately delayed securing vaccines to fight COVID-19.

Far-right President Jair Bolsonaro, who is under growing pressure to explain the deal with Bharat, said on Friday there were no irregularities in the contract for the Indian drugmaker's Covaxin shot.

"There is nothing wrong with the Covaxin contract, there is no overpricing," he said at a news conference in the interior of São Paulo.

The president, who was elected on an anti-graft platform, added that his enemies were trying to stain his government with unfounded accusations of corruption.

"I am incorruptible," he said.

The allegations regarding the Bharat contract threaten to damage Bolsonaro's pledge of zero tolerance for corruption in his government.

The coordinator of the Senate inquiry has called for protection for the Miranda brothers, and also for the owners of the Brazilian company Precisa Medicamentos, which acts as an intermediary for Bharat.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The contract is being probed by federal prosecutors and lawmakers to see why the government struck a speedy agreement with Bharat after COVID-19 vaccine offers from Pfizer Inc (NYSE:PFE) at a lower price were ignored.

Luis Ricardo Miranda and his lawmaker brother met with Bolsonaro in March and said they warned him of the suspicious contract, but that nothing was done to investigate the deal.

Legislator Luis Miranda said that Bolsonaro recognized that the situation was serious and told them that another congressman, Ricardo Barros, was involved in the Bharat deal.

Barros, the government's whip in the legislature's lower house, responded on Twitter that he had no involvement in the Bharat deal and that further investigation would show the president did not cite his name in the meeting.

Bolsonaro's press office did not immediately respond to a request for comment about implicating Barros.

Luis Ricardo Miranda, head of imports at the Health Ministry, told senators he refused to approve an import license because an invoice for a first shipment asked for up-front payment and was sent by a company not mentioned in the contract, Singapore-based Madison Biotech.

Miranda has told prosecutors he was pressured by Alex Lial Marinho, an aide to one of Bolsonaro's closest allies, former Health Minister Eduardo Pazuello. Miranda's account was backed up by his congressman brother.

The accusations raise awkward questions for Bolsonaro and Pazuello, who is facing criminal and civil investigations into his handling of the pandemic while minister.

On Thursday, Bolsonaro said Brazil never paid for or received any doses of the Covaxin shot, and pledged to take action if any corruption was discovered in his government.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In a statement issued in India, Bharat Biotech said, "We strongly refute and deny any kind of allegation or implication of any wrongdoing whatsoever with respect to the supply of COVAXIN." It said Madison Biotech was its global sales and marketing unit.

($1 = 4.9477 reais)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.